Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemoradiation vs Chemotherapy in Locally Advanced Pancreatic Cancer (CONKO-007)
NCT01827553Phase 3Completed
- Sponsor
- FAU Erlangen-Nürnberg Medical Faculty
- Start
- Apr 2013
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine in pancreatic cancer (PC) (2 arms), sponsored by FAU Erlangen-Nürnberg Medical Faculty. Primary endpoint: Overall Survival at 5 years. Started Apr 2013; status: completed.
02
Drugs
gemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT01827553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01827553.